Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma keeps profit forecast as prostate cancer drug sales rise

01/31/2020 | 03:29am EDT
FILE PHOTO: Astellas Pharma's logo is pictured at its headquarters in Tokyo

Japan's Astellas Pharma Inc reiterated its full-year operating profit forecast on Friday, as a jump in sales of its prostate cancer drug Xtandi countered overseas acquisition costs.

The company said it expects an operating profit of 263 billion yen ($2.4 billion) for the year ending March 31, higher than analysts' average expectation of 256 billion yen, according to IBES data from Refinitiv. Astellas reported an annual operating profit of 244 billion yen last year.

Shares in the company closed 2.4% higher in Tokyo compared with a 1% rise in the broader market.

Sales of Xtandi rose 18% to 298 billion yen in the third quarter ended Dec. 31.

However, core operating profit for the quarter was 3.3% lower, hurt partly by a 2.5% drop in revenue from Prograf, used to prevent rejection of organ transplants.

The company also said it will book a one-off charge of about $100 million in the fourth quarter related to its purchase of U.S.-based biotech Audentes Therapeutics Inc.

Astellas, the country's second-biggest drugmaker by sales, has ramped up overseas acquisitions to broaden its drug pipeline.

The company said in December it would pay up to $665 billion for Xyphos Biosciences Inc to expand its immuno-oncology business. Earlier that month, Astellas said it would purchase Audentes in a deal worth $2.65 billion to expand into genetic medicines.

Both Xyphos and Audentes are based in San Francisco, a hub for biotech companies that are fetching huge premiums for global pharma firms eager to bolster their drug pipelines.

Among other major Japanese pharma companies reporting earnings, Daiichi Sankyo Co, Japan's fourth-largest drug company by sales, raised its full-year operating profit forecast, citing lower taxes. It expects to earn 135 billion yen in the year ending March 31 versus 125 billion predicted in October.

Eisai Co, the partner of Biogen Inc on Alzheimer's disease drug candidate aducanumab, maintained its full-year operating profit forecast at 110 billion yen, a 16% increase from last year, driven by sales of its cancer drug Lenvima.

Daiichi Sankyo shares rose 1.6% while Eisai gained 2.2%.

By Rocky Swift


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 0.35% 1889 End-of-day quote.18.51%
BIOGEN INC. -0.63% 297.96 Delayed Quote.22.20%
DAIICHI SANKYO COMPANY, LIMITED 1.28% 2804.5 End-of-day quote.-20.66%
EISAI CO., LTD. 1.28% 8450 End-of-day quote.14.62%
SANKYO CO., LTD. 0.18% 2835 End-of-day quote.1.61%
All news about ASTELLAS PHARMA INC.
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Prog..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X..
CI
08/31ASTELLAS PHARMA : Announces Personnel Changes
PU
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approac..
PU
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
08/20FIBROGEN : Receives $120 Million Milestone Payment With Approval of Evrenzo in E..
MT
08/20ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
PU
08/19ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
AQ
08/19ASTELLAS PHARMA : Receives EC Approval for First-inClass EVRENZO (roxadustat) fo..
PU
More news
Financials
Sales 2022 1 325 B 12 052 M 12 052 M
Net income 2022 196 B 1 780 M 1 780 M
Net cash 2022 478 B 4 344 M 4 344 M
P/E ratio 2022 17,7x
Yield 2022 2,65%
Capitalization 3 500 B 31 855 M 31 840 M
EV / Sales 2022 2,28x
EV / Sales 2023 1,92x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 889,00 JPY
Average target price 2 451,54 JPY
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura Representative Director, VP & Head-Finance
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.18.51%31 807
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.84%209 456